Apnimed, Inc. (APMD)
Data as of , from SEC Form 4 filings.
See up to 3 months of APMD. The 7-day demo opens the 1M and 3M ranges and puts APMD on your watchlist.
Start 7-day demoLatest APMD insider trades
About Apnimed, Inc. (APMD)
Apnimed Inc is a late clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep related breathing diseases. The company's flagship product candidate, AD109, or Oxnimbi, is an investigational, fixed-dose oral combination of a novel anti-muscarinic and selective norepinephrine reuptake inhibitor for the treatment of obstructive sleep apnea (OSA).
- CAMBRIDGE, MA
- 2026
- Nasdaq
APMD Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 1 | 312,500 | $5.00M |
| Other acquisition / disposition | 16 | 45,595,707 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
APMD insider transactions (Form 4)
10110 Form 4 filings on record, the earliest from Aug 3, 2026, newest first.
| Traded | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Morningside Venture Investments Ltd - 10% Owner | Other | Class A Common Stock | 6,840,213 | - footnote F1 | - | |
| Morningside Venture Investments Ltd - 10% Owner | Other | Class A Common Stock | 6,840,213 | - footnote F3 | - | |
| Morningside Venture Investments Ltd - 10% Owner | Other | Common Stock | 6,840,213 | - footnote F3 | - | |
| Morningside Venture Investments Ltd - 10% Owner | Open-market purchase | Common Stock | 312,500 | $16.00 | $5.00M | |
| Morningside Venture Investments Ltd - 10% Owner | Other | Class A Common Stock | 75,624 | $14.40 footnote F4 | $1.09M | |
| Morningside Venture Investments Ltd - 10% Owner | Other | Class A Common Stock | 75,624 | - footnote F3 | - | |
| Morningside Venture Investments Ltd - 10% Owner | Other | Common Stock | 75,624 | - footnote F3 | - | |
| Morningside Venture Investments Ltd - 10% Owner | Other | Convertible Preferred Stock | 9,227,454 | $0.00 | - | |
| Morningside Venture Investments Ltd - 10% Owner | Other | Convertible Promissory Note | 1,088,986 footnote F4 | $0.00 | - | |
| ||||||
| Alpha Wave Ventures GP, Ltd - 10% Owner | Other | Common Stock | 1,001,651 | - footnote F1 | - | |
| Alpha Wave Ventures GP, Ltd - 10% Owner | Other | Common Stock | 534,214 | - footnote F1 | - | |
| Alpha Wave Ventures GP, Ltd - 10% Owner | Other | Common Stock | 4,006,611 | - footnote F1 | - | |
| Alpha Wave Ventures GP, Ltd - 10% Owner | Other | Common Stock | 1,512,480 | $13.50 | $20.42M | |
| Alpha Wave Ventures GP, Ltd - 10% Owner | Other | Series C-1 Preferred Stock | 1,351,227 | $0.00 | - | |
| Alpha Wave Ventures GP, Ltd - 10% Owner | Other | Series C-2 Preferred Stock | 720,655 | $0.00 | - | |
| Alpha Wave Ventures GP, Ltd - 10% Owner | Other | Series C-3 Preferred Stock | 5,404,918 | $0.00 | - | |
| Alpha Wave Ventures GP, Ltd - 10% Owner | Other | Convertible Notes | 0 | $0.00 | - footnote F5 | |
| ||||||
| Kevin Robert Lind - Officer | Derivative | Stock Option (Right to Buy) | 74,128 | $0.00 | - | |
| Kevin Robert Lind - Officer | Grant or award | Stock Option (Right to Buy) | 74,128 | $0.00 | - | |
| Kevin Robert Lind - Officer | Derivative | Stock Option (Right to Buy) | 1,186,278 | $0.00 | - | |
| Kevin Robert Lind - Officer | Grant or award | Stock Option (Right to Buy) | 1,186,278 | $0.00 | - | |
| Kevin Robert Lind - Officer | Grant or award | Stock Option (Right to Buy) | 108,916 | $0.00 | - | |
| Kevin Robert Lind - Officer | Derivative | Stock Option (Right to Buy) | 108,916 | $0.00 | - | |
| Kevin Robert Lind - Officer | Grant or award | Stock Option (Right to Buy) | 108,916 | $0.00 | - | |
| Michael B. Kelly - Officer | Derivative | Stock Option (Right to Buy) | 333,580 | $0.00 | - | |
| Michael B. Kelly - Officer | Grant or award | Stock Option (Right to Buy) | 333,580 | $0.00 | - | |
 Paul R. Fonteyne - Director | Derivative | Stock Option (Right to Buy) | 51,890 | $0.00 | - | |
| Paul R. Fonteyne - Director | Grant or award | Stock Option (Right to Buy) | 51,890 | $0.00 | - | |
| Paul R. Fonteyne - Director | Derivative | Stock Option (Right to Buy) | 44,477 | $0.00 | - | |
| Paul R. Fonteyne - Director | Grant or award | Stock Option (Right to Buy) | 44,477 | $0.00 | - | |
| Paul R. Fonteyne - Director | Grant or award | Stock Option (Right to Buy) | 44,477 | $0.00 | - | |
| Paul R. Fonteyne - Director | Derivative | Stock Option (Right to Buy) | 44,477 | $0.00 | - | |
| Paul R. Fonteyne - Director | Grant or award | Stock Option (Right to Buy) | 44,477 | $0.00 | - | |
| Gary Sender - Director | Derivative | Stock Option (Right to Buy) | 51,890 | $0.00 | - | |
| Gary Sender - Director | Grant or award | Stock Option (Right to Buy) | 51,890 | $0.00 | - | |
| Gary Sender - Director | Derivative | Stock Option (Right to Buy) | 44,477 | $0.00 | - | |
| Gary Sender - Director | Grant or award | Stock Option (Right to Buy) | 44,477 | $0.00 | - | |
| Gary Sender - Director | Grant or award | Stock Option (Right to Buy) | 44,477 | $0.00 | - | |
| Gary Sender - Director | Derivative | Stock Option (Right to Buy) | 44,477 | $0.00 | - | |
| Gary Sender - Director | Grant or award | Stock Option (Right to Buy) | 44,477 | $0.00 | - | |
| Paul J. Sekhri - Director | Open-market purchase | Common Stock | 12,500 | $16.00 | $200K | |
| Paul J. Sekhri - Director | Derivative | Stock Option (Right to Buy) | 169,468 | $0.00 | - | |
| Paul J. Sekhri - Director | Grant or award | Stock Option (Right to Buy) | 169,468 | $0.00 | - | |
| Paul J. Sekhri - Director | Grant or award | Stock Option (Right to Buy) | 155,558 | $0.00 | - | |
| Paul J. Sekhri - Director | Derivative | Stock Option (Right to Buy) | 155,558 | $0.00 | - | |
| Paul J. Sekhri - Director | Grant or award | Stock Option (Right to Buy) | 155,558 | $0.00 | - | |
| Paul J. Sekhri - Director | Grant or award | Stock Option (Right to Buy) | 22,238 | $0.00 | - | |
| Paul J. Sekhri - Director | Derivative | Stock Option (Right to Buy) | 22,238 | $0.00 | - | |
| Paul J. Sekhri - Director | Grant or award | Stock Option (Right to Buy) | 22,238 | $0.00 | - | |
| William A. Jones Jr. - Director | Grant or award | Stock Option (Right to Buy) | 44,477 | $0.00 | - | |
| William A. Jones Jr. - Director | Derivative | Stock Option (Right to Buy) | 44,477 | $0.00 | - | |
| William A. Jones Jr. - Director | Grant or award | Stock Option (Right to Buy) | 44,477 | $0.00 | - | |
| Lawrence G. Miller - Director | Derivative | Class A Common Stock | 92,431 | - footnote F1 | - | |
| Lawrence G. Miller - Director | Grant or award | Common Stock | 92,431 | - footnote F1 | - | |
| Lawrence G. Miller - Director | Other | Common Stock | 10,845 | - footnote F3 | - | |
| Lawrence G. Miller - Director | Derivative | Class A Common Stock | 88,954 | - footnote F1 | - | |
| Lawrence G. Miller - Director | Grant or award | Common Stock | 88,954 | - footnote F1 | - | |
| Lawrence G. Miller - Director | Derivative | Class A Common Stock | 88,954 | - footnote F1 | - | |
| Lawrence G. Miller - Director | Grant or award | Common Stock | 88,954 | - footnote F1 | - | |
| Lawrence G. Miller - Director | Derivative | Class A Common Stock | 88,954 | - footnote F1 | - | |
| Lawrence G. Miller - Director | Grant or award | Common Stock | 88,954 | - footnote F1 | - | |
| Lawrence G. Miller - Director | Derivative | Class A Common Stock | 88,954 | - footnote F1 | - | |
| Lawrence G. Miller - Director | Grant or award | Common Stock | 88,954 | - footnote F1 | - | |
| Lawrence G. Miller - Director | Other | Series A Preferred Stock | 10,845 | $0.00 | - | |
| Lawrence G. Miller - Director | Derivative | Stock Option (Right to Buy) | 688,042 | $0.00 | - | |
| Lawrence G. Miller - Director | Grant or award | Stock Option (Right to Buy) | 688,042 | $0.00 | - | |
| Lawrence G. Miller - Director | Derivative | Stock Option (Right to Buy) | 98,843 | $0.00 | - | |
| Lawrence G. Miller - Director | Grant or award | Stock Option (Right to Buy) | 98,843 | $0.00 | - | |
| Lawrence G. Miller - Director | Derivative | Stock Option (Right to Buy) | 302,541 | $0.00 | - | |
| Lawrence G. Miller - Director | Grant or award | Stock Option (Right to Buy) | 302,541 | $0.00 | - | |
| Lawrence G. Miller - Director | Derivative | Stock Option (Right to Buy) | 333,580 | $0.00 | - | |
| Lawrence G. Miller - Director | Grant or award | Stock Option (Right to Buy) | 333,580 | $0.00 | - | |
| Lawrence G. Miller - Director | Derivative | Stock Option (Right to Buy) | 333,580 | $0.00 | - | |
| Lawrence G. Miller - Director | Grant or award | Stock Option (Right to Buy) | 333,580 | $0.00 | - | |
| Lawrence G. Miller - Director | Derivative | Stock Option (Right to Buy) | 333,580 | $0.00 | - | |
| Lawrence G. Miller - Director | Grant or award | Stock Option (Right to Buy) | 333,580 | $0.00 | - | |
| Lawrence G. Miller - Director | Derivative | Stock Option (Right to Buy) | 59,303 | $0.00 | - | |
| Lawrence G. Miller - Director | Grant or award | Stock Option (Right to Buy) | 59,303 | $0.00 | - | |
| Lawrence G. Miller - Director | Derivative | Stock Option (Right to Buy) | 25,574 | $0.00 | - | |
| Lawrence G. Miller - Director | Grant or award | Stock Option (Right to Buy) | 25,574 | $0.00 | - | |
| Lawrence G. Miller - Director | Derivative | Stock Option (Right to Buy) | 74,128 | $0.00 | - | |
| Lawrence G. Miller - Director | Grant or award | Stock Option (Right to Buy) | 74,128 | $0.00 | - | |
| ||||||
| Dennis Patrick Molnar - Officer | Derivative | Class A Common Stock | 58,014 | - footnote F1 | - | |
| Dennis Patrick Molnar - Officer | Grant or award | Common Stock | 58,014 | - footnote F1 | - | |
| Dennis Patrick Molnar - Officer | Derivative | Stock Option (Right to Buy) | 330,210 | $0.00 | - | |
| Dennis Patrick Molnar - Officer | Grant or award | Stock Option (Right to Buy) | 330,210 | $0.00 | - | |
| Dennis Patrick Molnar - Officer | Derivative | Stock Option (Right to Buy) | 42,240 | $0.00 | - | |
| Dennis Patrick Molnar - Officer | Grant or award | Stock Option (Right to Buy) | 42,240 | $0.00 | - | |
| Dennis Patrick Molnar - Officer | Derivative | Stock Option (Right to Buy) | 148,788 | $0.00 | - | |
| Dennis Patrick Molnar - Officer | Grant or award | Stock Option (Right to Buy) | 148,788 | $0.00 | - | |
| Dennis Patrick Molnar - Officer | Derivative | Stock Option (Right to Buy) | 37,064 | $0.00 | - | |
| Dennis Patrick Molnar - Officer | Grant or award | Stock Option (Right to Buy) | 37,064 | $0.00 | - | |
| Dennis Patrick Molnar - Officer | Derivative | Stock Option (Right to Buy) | 28,539 | $0.00 | - | |
| Dennis Patrick Molnar - Officer | Grant or award | Stock Option (Right to Buy) | 28,539 | $0.00 | - | |
| Dennis Patrick Molnar - Officer | Derivative | Stock Option (Right to Buy) | 37,064 | $0.00 | - | |
| Dennis Patrick Molnar - Officer | Grant or award | Stock Option (Right to Buy) Stock Option (Right to Buy) | 37,064 | $0.00 | - | |
| Dennis Patrick Molnar - Officer | Derivative | Stock Option (Right to Buy) | 12,231 | $0.00 | - | |
| Dennis Patrick Molnar - Officer | Grant or award | Stock Option (Right to Buy) | 12,231 | $0.00 | - | |
| Dennis Patrick Molnar - Officer | Grant or award | Stock Option (Right to Buy) | 55,596 | $0.00 | - | |
| Dennis Patrick Molnar - Officer | Derivative | Stock Option (Right to Buy) | 55,596 | $0.00 | - | |
| Dennis Patrick Molnar - Officer | Grant or award | Stock Option (Right to Buy) | 55,596 | $0.00 | - | |
| ||||||
Item 2.02, 9.01
Item 5.03, 9.01
APMD insider trading FAQ
What is the latest insider trade for APMD?
Apnimed, Inc. (APMD) had 2 insider filings in the last 90 days, with the most recent on 5 August 2026. The full record for APMD runs to 10 Form 4 filings, the earliest from 3 August 2026. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying APMD stock?
1 insider purchase of APMD was filed in the last 90 days, totaling $5.00M.
How many insiders are selling APMD stock?
No insider sales of APMD were filed in the last 90 days.
Where can I see APMD SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects APMD Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Morningside Venture Investments Ltd view on EDGAR
- - Alpha Wave Ventures GP, Ltd view on EDGAR
- - Kevin Robert Lind view on EDGAR
- - Michael B. Kelly view on EDGAR
- - Paul R. Fonteyne view on EDGAR
- - Gary Sender view on EDGAR
- - Paul J. Sekhri view on EDGAR
- - William A. Jones Jr. view on EDGAR
- - Lawrence G. Miller view on EDGAR
Related companies with recent insider activity
Learn more
- How to read insider buying signals
- What an open-market purchase by an insider can and cannot tell you.
- Insider activity in Health Care
- Where APMD's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow APMD with a 7-day demo
- APMD on your watchlist
- Every APMD Form 4 filing on record
- Up to 3 months of APMD price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
